NeOnc Technologies Holdings, Inc. Common Stock
Follow $NTHI
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $NTHI by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredHighest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is NTHI moving today?
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
NTHI overview
Related filings and maps
Congress activity in NTHI
No receipt-qualified Congressional disclosure is present for NTHI in the cached public ledger.
NTHI contract awards, year to date.
Public federal awards linked to this ticker.
NTHI lobbying filings, year to date.
Registered lobbying filings matched to NeOnc Technologies Holdings, Inc. Common Stock.